Print

OXiGENE (OXGN) Expands ZYBRESTAT Named Patient Program With Azanta A/S  
8/23/2012 10:06:36 AM

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company has amended the Limited Distribution Agreement, established in December 2011, with Azanta Danmark A/S to include additional territories. The territory originally included the European Union, including the Nordic countries and Switzerland, and Canada. The expanded territories now include Israel and South Korea. The Limited Distribution Agreement provides access to ZYBRESTAT® for the treatment of patients in Europe with anaplastic thyroid cancer (ATC) on a compassionate use basis via a named patient program, managed by Azanta A/S. The Agreement provides a regulatory mechanism to allow healthcare professionals in Europe to prescribe ZYBRESTAT to individual ATC patients while it is still in development.
//-->